伊沙佐米成功治疗由骨髓增生异常综合征转化而来的复发难治性急性髓系白血病。
Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome.
作者信息
Oka Satoko, Ono Kazuo
机构信息
Division of Hematology Japanese Red Cross Society Wakayama Medical Center Wakayama Japan.
Division of Pathology Japanese Red Cross Society Wakayama Medical Center Wakayama Japan.
出版信息
Clin Case Rep. 2021 Jun 23;9(6):e04287. doi: 10.1002/ccr3.4287. eCollection 2021 Jun.
Abstract
Elevated NF-kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF-kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia, but maintained complete remission after monotherapy with ixazomib.
摘要
在骨髓增生异常综合征/急性髓系白血病（MDS/AML）患者的原始骨髓细胞中已发现核因子-κB（NF-κB）水平升高，这表明NF-κB是MDS/AML的一个治疗靶点。我们在此描述了一名不符合造血干细胞移植（SCT）条件的MDS患者，该患者在接受阿扎胞苷和硼替佐米治疗后转变为白血病，但在接受伊沙佐米单药治疗后维持完全缓解。
相似文献
1
Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome.
Clin Case Rep. 2021 Jun 23;9(6):e04287. doi: 10.1002/ccr3.4287. eCollection 2021 Jun.
2
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):244-51. doi: 10.1016/j.clml.2012.03.003. Epub 2012 Apr 24.
3
[High Risk Factors for Transformation into Acute myeloid Leukemia in Patients with Intermediate and High Risk Myelodysplastic syndrome].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Apr;28(2):558-566. doi: 10.19746/j.cnki.issn.1009-2137.2020.02.034.
4
Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Acta Haematol. 2000;102(3):115-23. doi: 10.1159/000040984.
5
Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Pathol Oncol Res. 2019 Jul;25(3):1175-1180. doi: 10.1007/s12253-018-00574-0. Epub 2019 Jan 6.
6
Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Am J Hematol. 2001 Dec;68(4):237-45. doi: 10.1002/ajh.1188.
7
The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
Cancer. 2003 Jan 15;97(2):441-9. doi: 10.1002/cncr.11036.
8
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
Leuk Res. 2013 Nov;37(11):1502-8. doi: 10.1016/j.leukres.2013.09.003. Epub 2013 Sep 8.
9
Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Transplant Cell Ther. 2023 Jul;29(7):454.e1-454.e8. doi: 10.1016/j.jtct.2023.03.025. Epub 2023 Mar 24.
10
NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome.
Blood. 2006 Feb 1;107(3):1156-65. doi: 10.1182/blood-2005-05-1989. Epub 2005 Oct 13.
引用本文的文献
1
Bortezomib Eliminates Persistent Infection through Rapid and Specific Host Cell Apoptosis.
Int J Mol Sci. 2022 Jul 4;23(13):7434. doi: 10.3390/ijms23137434.
本文引用的文献
1
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
Clin Cancer Res. 2019 Jul 15;25(14):4231-4237. doi: 10.1158/1078-0432.CCR-18-3886. Epub 2019 Apr 16.
2
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.
Am J Hematol. 2017 Jul;92(7):674-682. doi: 10.1002/ajh.24746. Epub 2017 Jun 9.
3
The role of the proteasome in AML.
Blood Cancer J. 2016 Dec 2;6(12):e503. doi: 10.1038/bcj.2016.112.
4
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).
Leukemia. 2016 Sep;30(9):1956-9. doi: 10.1038/leu.2016.111. Epub 2016 May 2.
5
Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.
Clin Cancer Res. 2016 Apr 15;22(8):1978-88. doi: 10.1158/1078-0432.CCR-15-1440. Epub 2015 Dec 3.
6
Update on proteasome inhibitors in multiple myeloma.
Clin Adv Hematol Oncol. 2014 Mar;12(3):179-81.
7
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Blood. 2014 Aug 14;124(7):1038-46. doi: 10.1182/blood-2014-01-548826. Epub 2014 Jun 11.
8
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Blood. 2014 Aug 14;124(7):1047-55. doi: 10.1182/blood-2014-01-548941. Epub 2014 Jun 5.
9
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
J Clin Oncol. 2013 Mar 1;31(7):923-9. doi: 10.1200/JCO.2012.45.2177. Epub 2012 Nov 5.
10
Proteasome inhibitors in multiple myeloma: 10 years later.
Blood. 2012 Aug 2;120(5):947-59. doi: 10.1182/blood-2012-04-403733. Epub 2012 May 29.
Zotero 插件